A team of researchers at British Pharmaceutical company AstraZeneca has developed a new antibody drug that increases the level of lipoprotein cholesterol (HDL-C) in test monkeys and humans. In their paper published in the journal Science Translational Medicine, the group describes the drug and how well it worked when tested in monkeys and humans.